MONISTAT 3 (miconazole nitrate) by Design Pharmaceuticals is clinical pharmacology miconazole nitrate exhibits fungicidal activity in vitro against species of the genus candida. First approved in 1984.
Drug data last refreshed 1h ago
MONISTAT 3 is a miconazole nitrate vaginal suppository indicated for vulvovaginal candidiasis and other fungal infections. The drug exhibits fungicidal activity against Candida species through an unknown pharmacologic mechanism. It is administered intravaginally with minimal systemic absorption.
Product is approaching loss of exclusivity with moderate competitive pressure (30), indicating declining team expansion and focus on generic transition strategies.
CLINICAL PHARMACOLOGY Miconazole nitrate exhibits fungicidal activity in vitro against species of the genus Candida. The pharmacologic mode of action is unknown. Following intravaginal administration of miconazole nitrate, small amounts are absorbed. Administration of a single dose of miconazole…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants
Worked on MONISTAT 3 at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Zero linked job count reflects the product's mature LOE status with minimal hiring momentum; roles focus on defending market share, managing generic transition, and optimizing operational efficiency. Career growth on this asset is limited, but experience managing LOE products is valuable for portfolio management expertise.